Results 181 to 190 of about 50,964 (281)

Castration Resistance Accelerates Prostate Cancer Kinetics

The Prostate, Volume 86, Issue 9, Page 1021-1027, June 15, 2026.
ABSTRACT Background Prostate cancer can be an indolent disease with which patients can live for many years. Thus, an understanding of how therapy and its ensuing resistance affect prostate cancer kinetics may guide efforts to determine optimal timing of therapy initiation.
Sheila Jonnatan, Luka Cavka, Angelo M. De Marzo, Samuel R. Denmeade, Mark C. Markowski, Emmanuel S. Antonarakis, Bruce J. Trock, Catherine H. Marshall, Ravi A. Madan, David J. Einstein, Laura A. Sena   +10 more
wiley   +1 more source

The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer

The Prostate, Volume 86, Issue 9, Page 1043-1052, June 15, 2026.
ABSTRACT Purpose Previous studies have demonstrated an association between PSMA‐PET SUVmax and poorer survival outcomes in patients with mCRPC. However, limited data are available in mHSPC. We aim to investigate the relationship between baseline PSMA‐PET SUVmax and rPFS in patients with mHSPC.
Cevat İlteriş Kıkılı, Caner Kapar, Feyyaz Hazar Yağmur, Esra Arslan, Bahadır Köylü, Fatih Kemik, Buğra Han Esen, Nazan Demir, İlkay Gültürk, Murat Polat, Fatih Selçukbiricik, Deniz Tural   +11 more
wiley   +1 more source

Impact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer

The Prostate, Volume 86, Issue 9, Page 1053-1060, June 15, 2026.
ABSTRACT Background Early deep prostate‐specific antigen (PSA) decline after the initiation of androgen receptor signaling inhibitor (ARSI) therapy is associated with favorable long‐term outcomes in metastatic castration‐sensitive prostate cancer (mCSPC).
Kazuma Yukihiro, Yohei Sekino, Keisuke Goto, Kohei Saito, Kenta Fujiyama, Yoshito Kagiyama, Yoshimasa Kurimura, Kenichiro Fukuoka, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +14 more
wiley   +1 more source

Improved Chemosensitivity in Metastatic Castration-Resistant Prostate Cancer: The Synergistic Effects of S-Adenosylmethionine and Cabazitaxel. [PDF]

Cancer Med
Arpino R, Cadoni F, Pagano C, Coppola L, Del Vecchio V, Nigam A, Mosca L, Porcelli M.   +7 more
europepmc   +1 more source

Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target

The Prostate, Volume 86, Issue 9, Page 1061-1068, June 15, 2026.
ABSTRACT Introduction The clinical relevance of HER2 expression profile in solid cancers has expanded with the evolving landscape of HER2 targeting agents. This systematic review and meta‐analysis aim to detail the prevalence of HER (over)expression in prostate cancer and identify patient/disease subgroups with enriched HER2 overexpression.
Jacky T. F. Luk, Alex H. Lin, Esther K. C. Cheung, Renald Meçani, Taulant Muka, Jana Nano, Joanna K. M. Ng, Matthew K. L. Chiu, Bryan C. W. Li, Rong Na, Joshua J. X. Li   +10 more
wiley   +1 more source

Phase Separation of NFIB Suppresses SLC3A2-Mediated Ferroptosis in Castration-Resistant Prostate Cancer. [PDF]

Adv Sci (Weinh)
Li Q, Chen D, Xia Y, Long Y, Huang N, Li R, Shi M, Kadier M, Luo H, Chen X, Liu H, Jiang G.   +11 more
europepmc   +1 more source

Mediation Analysis With Bayesian Nonlinear Joint Models: Evaluation of the Treatment Causal Pathways Between Tumor Growth Kinetics and Overall Survival

Statistics in Medicine, Volume 45, Issue 13-14, June 2026.
ABSTRACT Understanding the mechanisms through which anti‐cancer treatments influence survival is central to improving drug development and evaluation. In this work, we develop a Bayesian joint modeling framework for mediation analysis to quantify the extent to which tumor size dynamics mediate the effect of treatment on overall survival (OS). Our model
Georgios Kazantzidis, Francois Mercier, Virginie Rondeau   +2 more
wiley   +1 more source

TLN1 interacts with NGFR and suppresses the development of castration-resistant prostate cancer by upregulating NGFR. [PDF]

Front Immunol
Li S, Chen A, Guo C, Gu C, Tang Z, Shen S, Yang D, Mi Y.   +7 more
europepmc   +1 more source

Identification of genetically predicted protein biomarkers and drug targets for prostate cancer via Mendelian randomization

VIEW, Volume 7, Issue 3, June 2026.
Prostate cancer, a leading cause of cancer in men globally, urgently requires improved diagnostic and treatment strategies. This study analyzed large genetic datasets and identified five key proteins (THBD, DST, IFI27L2, OSBPL10, PPP1R14A) that either increase or decrease cancer risk, while also exploring their roles in immune response and potential ...
Maoping Cai, Tianming Peng, Zhiyue Xie, Chuqian Zhen, Chen Yao, Nan Peng, Qianyi Li, Yuzhong Yu, Jiming Bao, Xian‐Lu Song, Mingkun Chen, Shan‐Chao Zhao   +11 more
wiley   +1 more source

Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for all. [PDF]

Transl Androl Urol
de Souza VPB, Barata PC.
europepmc   +1 more source